FDA issues a Complete Response Letter for GTx' toremifene NDA
Links shared publicly online about this topic.
- 1,631total visits
FDA issues a Complete Response Letter for GTx' toremifene NDA
GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).
View full resource at news-medical.net
Tags: Emergency, Fracture, Cancer, Prostate Cancer, Prostate, Drug, Men's Health, FDA
Most Recently Shared on November 2, 2009 at 6:26 pm By:
Prostate Cancer: FDA issues a Complete Response Letter for GTx' toremifene NDA: GTx, Inc. today.. http://bit.ly/41AWz5
Advertisement
